Aldeyra疗法 ALDX 深 沪
等待开盘 11-04 09:30:00 美东时间
5.23
+0.160
+3.16%
华盛通- 最 高5.24
- 今 开5.07
- 成交量 63.97万股
- 最 低 5.04
- 昨 收 5.07
- 总市值 3.13亿
- 52周最高 7.20
- 市盈率 静 --
- 换手率 1.07%
- 52周最低 1.14
- 委 比 -52.40%
- 总股本 5989.56万
- 历史最高 16.70
- 量 比 0.83
- 振 幅 3.94%
- 历史最低 1.14
- 每 手 1
- 风险率 1.38%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多4 Biotech Stocks Seeing Explosive Momentum Gains
The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the verge of breaking out. Here's a look at several momentum standouts in the biotech space that appear to be rapidly gaining strength.
10-07 23:19
Alkermes appoints new CFO
Joshua Reed has been appointed as chief financial officer of Alkermes (NASDAQ:ALKS), effective September 15, 2025. Reed previously served as CFO of Omega Therapeutics and Aldeyra Therapeutics (ALDX), ...
09-12 21:08
Aldeyra Wins EMA Orphan Drug Status for ADX-2191 to Treat Rare Eye Cancer
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that the European Medicines Agency (EMA) has granted Orphan Designation for ADX-2191 (methotrexate intravitreal injection, USP) for the treatment of
08-28 19:22
Aldeyra Therapeutics Says FDA Grants Fast Track Designation For ADX-2191 For Treatment Of Retinitis Pigmentosa
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 (methotrexate intravitreal injection, USP) for the
08-19 19:05
Aldeyra says FDA accepted resubmitted marketing application for lead drug
Aldeyra Therapeutics (NASDAQ:ALDX) announced on Thursday that the U.S. Food and Drug Administration (FDA) accepted for review its resubmitted New Drug Application (NDA) for its lead drug reproxalap, t...
07-17 19:42
FDA Accepts Aldeyra’s Reproxalap Application for Review
Aldeyra Therapeutics ( ($ALDX) ) has provided an update. On July 17, 2025, Alde...
07-17 19:27
Aldeyra resubmits Reproxalap's marketing application to FDA
Aldeyra Therapeutics (NASDAQ:ALDX) said that it has resubmitted its marketing application to the U.S. FDA for its dry eye treatment, reproxalap. According to the FDA, the resubmission includes only ne...
06-17 22:39
Aldeyra Resubmits Reproxalap NDA to FDA
An update from Aldeyra Therapeutics ( ($ALDX) ) is now available. On June 17, 2...
06-17 19:29
Aldeyra Resubmits Eye Drug for FDA Review After New Trial Clears Key Hurdle in Treating Dry Eye
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune‑mediated and metabolic diseases, today announced the
06-17 19:03
Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019
FDA approves Alcon's Tryptyr for dry eye disease, backed by Phase 3 trials showing strong efficacy in increasing natural tear production.
05-30 01:28
